LCM
ANTX icon

Landscape Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Landscape Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Sell
298,166
-133,594
-31% -$276K 0.06% 385
2025
Q4 		$492K Sell
431,760
-24,703
-5% -$28.9K 0.03% 487
2025
Q3 		$580K Sell
456,463
-38,933
-8% -$44.5K 0.04% 438
2025
Q2 		$525K Buy
+495,396
New +$590K 0.04% 446

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Landscape Capital Management's ANTX Position: Q1 2026 in Review

Landscape Capital Management reduced its AN2 Therapeutics (ANTX) stake by 31% in Q1 2026, selling an estimated $276K and leaving 298,166 shares worth $1.02M. The position accounts for 0.06% of the portfolio, ranked #385.

Landscape Capital Management first reported a position in ANTX in Q2 2025 and has held it in 4 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Landscape Capital Management held 298,166 shares of AN2 Therapeutics worth $1.02M as of Q1 2026.
  • Landscape Capital Management sold 133,594 AN2 Therapeutics shares in Q1 2026, an estimated $276K.
  • AN2 Therapeutics made up 0.06% of Landscape Capital Management's portfolio in Q1 2026, its #385 holding.
  • Landscape Capital Management first reported a position in AN2 Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Landscape Capital Management's 13F filing for Q1 2026, filed 12 May 2026.